2244960-75-4
2244960-75-4
Chemical Structure
Bepranemab
Synonym(s): UCB 0107
- CAS No.: 2244960-75-4
- Formula:N/A
- Molecular Weight:(145.52 kDa)
IUPAC Name: 5-(propoxy-d7)-1H-benzo[d]imidazol-2-amine
SMILES: [Bepranemab]
Biological Activity: Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bepranemab | 99.90% | Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Neațu M, et al. Monoclonal Antibody Therapy in Alzheimer's Disease. Pharmaceutics. 2023 Dec 29;16(1):60. [Content Brief]
- [2]. Barton, M.E., et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003. Alzheimer's Dement., 17: e057586.
Keywords
